Compare GAIA & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | ATYR |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.9M | 69.2M |
| IPO Year | 1999 | N/A |
| Metric | GAIA | ATYR |
|---|---|---|
| Price | $3.41 | $0.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 8 |
| Target Price | ★ $9.00 | $4.20 |
| AVG Volume (30 Days) | 57.8K | ★ 2.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,000,000.00 | N/A |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $11.08 | $18,728.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 48.15 | N/A |
| 52 Week Low | $2.93 | $0.64 |
| 52 Week High | $6.39 | $7.29 |
| Indicator | GAIA | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 52.94 | 54.09 |
| Support Level | $3.34 | $0.67 |
| Resistance Level | $4.23 | $1.09 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 82.47 | 44.21 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.